Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

dengue shock syndrome (DSS) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

dengue shock syndrome

MONDO:0000248

Also known as:DSS

Find Clinical TrialsTrials

Overview

A dengue disease that involves the most severe form of dengue fever, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom easy bruising, has symptom blood spots, has symptom bleeding gums, and has symptom nosebleeds. It is accompanied by circulatory collapse, involves hypotension, narrow pulse pressure (less than or equal to 20mm Hg), or frank shock. The shock occurs after two to six days of symptoms, followed by collapse, weak pulse, and blueness around the mouth.

Treatments1 FDA approved

Clinical Trials7 registered · 5 recruiting

Diagnosis

Biomarker and diagnostic research for dengue shock syndrome has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for dengue shock syndrome, including DOPAMINE HYDROCHLORIDE (DOPAMINE HYDROCHLORIDE AND DEXTROSE, approved 1987).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

7 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 2 PHASE2, 1 PHASE1, 2 NA. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07002021](https://clinicaltrials.gov/study/NCT07002021)

Data assembled from 4 of 12 sources · Last updated Sep 17, 2026, 10:10 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of DOPAMINE HYDROCHLORIDE AND DEXTROSE for managing dengue shock syndrome?
→Are any of the 7 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	32	25%
Disease patterns and progression	26	20%
Laboratory research	25	20%
Patient case studies	20	16%
Testing and diagnosis research	10	8%
Clinical study results	10	8%
New treatment approaches	4	3%
Other research	1	1%

dengue shock syndrome

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications